BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wyles DL, Sulkowski MS, Dieterich D. Management of Hepatitis C/HIV Coinfection in the Era of Highly Effective Hepatitis C Virus Direct-Acting Antiviral Therapy. Clin Infect Dis 2016;63 Suppl 1:S3-S11. [PMID: 27363438 DOI: 10.1093/cid/ciw219] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 6.6] [Reference Citation Analysis]
Number Citing Articles
1 Tempestilli M, Fabbri G, Mastrorosa I, Timelli L, Notari S, Bellagamba R, Libertone R, Lupi F, Zaccarelli M, Antinori A, Agrati C, Ammassari A. Plasma trough concentrations of antiretrovirals in HIV-infected persons treated with direct-acting antiviral agents for hepatitis C in the real world. J Antimicrob Chemother 2018;73:160-4. [PMID: 29106584 DOI: 10.1093/jac/dkx348] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Virseda-Berdices A, Rojo D, Martínez I, Berenguer J, González-García J, Brochado-Kith O, Fernández-Rodríguez A, Díez C, Hontañon V, Pérez-Latorre L, Micán R, Barbas C, Resino S, Jiménez-Sousa MA; ESCORIAL Study Group. Metabolomic changes after DAAs therapy are related to the improvement of cirrhosis and inflammation in HIV/HCV-coinfected patients. Biomed Pharmacother 2022;147:112623. [PMID: 35032770 DOI: 10.1016/j.biopha.2022.112623] [Reference Citation Analysis]
3 Lapa D, Del Porto P, Minosse C, D'Offizi G, Antinori A, Capobianchi MR, Visco-Comandini U, McPhee F, Garbuglia AR, Zaccarelli M. Clinical Relevance of Torque Teno Virus (TTV) in HIV/HCV Coinfected and HCV Monoinfected Patients Treated with Direct-Acting Antiviral Therapy. J Clin Med 2021;10:2092. [PMID: 34068071 DOI: 10.3390/jcm10102092] [Reference Citation Analysis]
4 Behara R, Reau N. Updates on hepatitis C virus therapy in the direct-acting antiviral era. Current Opinion in Gastroenterology 2017;33:115-9. [DOI: 10.1097/mog.0000000000000350] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.2] [Reference Citation Analysis]
5 Martin TCS, Rauch A, Salazar-Vizcaya L, Martin NK. Understanding and Addressing Hepatitis C Virus Reinfection Among Men Who Have Sex with Men. Infect Dis Clin North Am 2018;32:395-405. [PMID: 29778262 DOI: 10.1016/j.idc.2018.02.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
6 Roberson JL, Lagasca AM, Kan VL. Comparison of the Hepatitis C Continua of Care Between Hepatitis C Virus/HIV Coinfected and Hepatitis C Virus Mono-Infected Patients in Two Treatment Eras During 2008-2015. AIDS Res Hum Retroviruses 2018;34:148-55. [PMID: 28974107 DOI: 10.1089/AID.2017.0092] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
7 Chen YC, Thio CL, Cox AL, Ruhs S, Kamangar F, Wiberg KJ. Trends in hepatitis C treatment initiation among HIV/hepatitis C virus-coinfected men engaged in primary care in a multisite community health centre in Maryland: a retrospective cohort study. BMJ Open 2019;9:e027411. [PMID: 30928964 DOI: 10.1136/bmjopen-2018-027411] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Guss D, Sherigar J, Rosen P, Mohanty SR. Diagnosis and Management of Hepatitis C Infection in Primary Care Settings. J Gen Intern Med. 2018;33:551-557. [PMID: 29352420 DOI: 10.1007/s11606-017-4280-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
9 Gao LH, Nie QH, Zhao XT. Drug-Drug Interactions of Newly Approved Direct-Acting Antiviral Agents in Patients with Hepatitis C. Int J Gen Med 2021;14:289-301. [PMID: 33536776 DOI: 10.2147/IJGM.S283910] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Venuto CS, Cramer YS, Rosenkranz SL, Sulkowski M, Wyles DL, Cohen DE, Schmidt J, Alston-Smith BL, Morse GD. Raltegravir pharmacokinetics before and during treatment with ombitasvir, paritaprevir/ritonavir plus dasabuvir in adults with human immunodeficiency virus-1 and hepatitis C virus coinfection: AIDS Clinical Trials Group sub-study A5334s. Br J Clin Pharmacol 2020;86:132-42. [PMID: 31656054 DOI: 10.1111/bcp.14148] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Marathe G, Moodie EEM, Brouillette M, Cox J, Delaunay CL, Cooper C, Hull M, Gill J, Walmsley S, Pick N, Klein MB; Canadian Co-Infection Cohort. Depressive symptoms are no longer a barrier to HCV treatment initiation in the HIV–HCV co-infected population in Canada. Antiviral Therapy 2022;27:135965352110676. [DOI: 10.1177/13596535211067610] [Reference Citation Analysis]
12 Chawla A, Wang C, Patton C, Murray M, Punekar Y, de Ruiter A, Steinhart C. A Review of Long-Term Toxicity of Antiretroviral Treatment Regimens and Implications for an Aging Population. Infect Dis Ther 2018;7:183-95. [PMID: 29761330 DOI: 10.1007/s40121-018-0201-6] [Cited by in Crossref: 42] [Cited by in F6Publishing: 31] [Article Influence: 10.5] [Reference Citation Analysis]
13 Sarmento-Castro R, Méndez J, Horta A, Gonçalves C, Vasconcelos O, Seabra J, Abreu M, Gonçalves MJ, Santos MJ, Tavares AP. Hepatitis C treatment outcome in former or current intravenous drug users coinfected with HIV, with or without directly observed therapy. Infect Dis (Lond) 2021;53:9-18. [PMID: 32820689 DOI: 10.1080/23744235.2020.1806352] [Reference Citation Analysis]
14 Cotter TG, Wang J, Lieber SR, Odenwald MA, Rich NE, Marrero JA, Singal AG, Mitchell MC, Aronsohn A, Charlton M, Fung J. "Raising HOPE": Improved Outcomes for HIV/HCV-coinfected Liver Transplant Recipients in the Direct-acting Antiviral Era. Transplant Direct 2021;7:e707. [PMID: 34124343 DOI: 10.1097/TXD.0000000000001154] [Reference Citation Analysis]
15 Hartnell F, Brown A, Capone S, Kopycinski J, Bliss C, Makvandi-Nejad S, Swadling L, Ghaffari E, Cicconi P, Del Sorbo M, Sbrocchi R, Esposito I, Vassilev V, Marriott P, Gardiner CM, Bannan C, Bergin C, Hoffmann M, Turner B, Nicosia A, Folgori A, Hanke T, Barnes E, Dorrell L. A Novel Vaccine Strategy Employing Serologically Different Chimpanzee Adenoviral Vectors for the Prevention of HIV-1 and HCV Coinfection. Front Immunol 2018;9:3175. [PMID: 30713538 DOI: 10.3389/fimmu.2018.03175] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
16 Lazarus JV, Pericàs JM, Picchio C, Cernosa J, Hoekstra M, Luhmann N, Maticic M, Read P, Robinson EM, Dillon JF. We know DAAs work, so now what? Simplifying models of care to enhance the hepatitis C cascade. J Intern Med 2019;286:503-25. [PMID: 31472002 DOI: 10.1111/joim.12972] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 11.7] [Reference Citation Analysis]
17 Kamal SM. Hepatitis C Treatment in the Era of Direct-Acting Antiviral Agents. Hepatitis C in Developing Countries. Elsevier; 2018. pp. 209-46. [DOI: 10.1016/b978-0-12-803233-6.00017-5] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
18 Martin NK, Jansen K, An der Heiden M, Boesecke C, Boyd A, Schewe K, Baumgarten A, Lutz T, Christensen S, Thielen A, Mauss S, Rockstroh JK, Skaathun B, Ingiliz P. Eliminating Hepatitis C Virus Among Human Immunodeficiency Virus-Infected Men Who Have Sex With Men in Berlin: A Modeling Analysis. J Infect Dis 2019;220:1635-44. [PMID: 31301142 DOI: 10.1093/infdis/jiz367] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
19 Yin X, Kong L, Du P, Jung J. Effects of direct-acting antiviral treatment on reducing mortality among Medicare beneficiaries with HIV and HCV coinfection. AIDS Care 2021;:1-8. [PMID: 34581640 DOI: 10.1080/09540121.2021.1981221] [Reference Citation Analysis]
20 Greeley ZW, Giannasca NJ, Porter MJ, Margulies BJ. Acyclovir, cidofovir, and amenamevir have additive antiviral effects on herpes simplex virus TYPE 1. Antiviral Res 2020;176:104754. [PMID: 32114034 DOI: 10.1016/j.antiviral.2020.104754] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Parisi SG, Basso M, Mengoli C, Scaggiante R, Andreis S, Franzetti MM, Cattelan AM, Zago D, Cruciani M, Andreoni M, Piovesan S, Palù G, Alberti A. Liver stiffness is not associated with short- and long-term plasma HIV RNA replication in immunocompetent patients with HIV infection and with HIV/HCV coinfection. Ann Gastroenterol 2017;30:534-41. [PMID: 28845109 DOI: 10.20524/aog.2017.0175] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
22 Rossi C, Young J, Martel-Laferrière V, Walmsley S, Cooper C, Wong A, Gill MJ, Klein MB; Canadian Co-Infection Cohort Investigators . Direct-Acting Antiviral Treatment Failure Among Hepatitis C and HIV-Coinfected Patients in Clinical Care. Open Forum Infect Dis 2019;6:ofz055. [PMID: 30882016 DOI: 10.1093/ofid/ofz055] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
23 MacBrayne CE, Kiser JJ. Pharmacologic Considerations in the Treatment of Hepatitis C Virus in Persons With HIV. Clin Infect Dis 2016;63 Suppl 1:S12-23. [PMID: 27363437 DOI: 10.1093/cid/ciw220] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
24 Johnson TM, Sison R, Fallon JP, Shukla PP, Bhattarai S, Galang H, Habeeb R, Slim J. Clinical experience with dolutegravir/abacavir/lamivudine in HIV-HCV co-infected patients treated with a sofosbuvir-based regimen-safety and efficacy. HIV Clin Trials 2016;17:242-5. [PMID: 27846791 DOI: 10.1080/15284336.2016.1248625] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
25 Virlogeux V, Zoulim F, Pugliese P, Poizot-Martin I, Valantin MA, Cuzin L, Reynes J, Billaud E, Huleux T, Bani-Sadr F, Rey D, Frésard A, Jacomet C, Duvivier C, Cheret A, Hustache-Mathieu L, Hoen B, Cabié A, Cotte L; Dat’AIDS Study Group. Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination. BMC Med 2017;15:217. [PMID: 29249202 DOI: 10.1186/s12916-017-0979-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 4.6] [Reference Citation Analysis]
26 Meissner EG. Update in HIV-hepatitis C virus coinfection in the direct acting antiviral era. Curr Opin Gastroenterol 2017;33:120-7. [PMID: 28234770 DOI: 10.1097/MOG.0000000000000347] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
27 Ramesh D, Vijayakumar BG, Kannan T. Advances in Nucleoside and Nucleotide Analogues in Tackling Human Immunodeficiency Virus and Hepatitis Virus Infections. ChemMedChem 2021;16:1403-19. [PMID: 33427377 DOI: 10.1002/cmdc.202000849] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
28 Rockstroh JK, Orkin C, Viani RM, Wyles D, Luetkemeyer AF, Lazzarin A, Soto-Malave R, Nelson MR, Bhagani SR, Klinker HHF, Rizzardini G, Girard PM, Tural C, Shulman NS, Mobashery N, Hu YB, Fredrick LM, Pilot-Matias T, Trinh R, Gane E. Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2. Open Forum Infect Dis 2017;4:ofx154. [PMID: 28948180 DOI: 10.1093/ofid/ofx154] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
29 Bruno G, Saracino A, Scudeller L, Fabrizio C, Dell'Acqua R, Milano E, Milella M, Ladisa N, Monno L, Angarano G. HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ? Int J Infect Dis 2017;62:64-71. [PMID: 28728927 DOI: 10.1016/j.ijid.2017.07.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
30 Tran AN, Lim JK. Hepatitis C: How Good Are Real-Life Data and Do Generics Work. Gastroenterol Clin North Am 2020;49:279-99. [PMID: 32389363 DOI: 10.1016/j.gtc.2020.01.006] [Reference Citation Analysis]
31 Shumway M, Luetkemeyer AF, Peters MG, Johnson MO, Napoles TM, Riley ED. Direct-acting antiviral treatment for HIV/HCV patients in safety net settings: patient and provider preferences. AIDS Care 2019;31:1340-7. [PMID: 30829533 DOI: 10.1080/09540121.2019.1587353] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
32 Li Y, Li L, Liu J, Zhang DW, Zhao F, Wang L, Mahemure A, Xie R, Lei S, Cai W, Wang X, Shu Z, Chen X, Wang H, Wang FS. Tolerable and curable treatment in HIV/HCV co-infected patients using anti-HCV direct antiviral agents: a real-world observation in China. Hepatol Int 2018;12:465-73. [PMID: 30203381 DOI: 10.1007/s12072-018-9891-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
33 Patel SV, Jayaweera DT, Althoff KN, Eron JJ, Radtchenko J, Mills A, Moyle G, Santiago S, Sax PE, Gillman J, Mounzer K, Elion RA, Huhn GD. Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV. PLoS One 2020;15:e0228847. [PMID: 32053682 DOI: 10.1371/journal.pone.0228847] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
34 Torres HA, Economides MP, Angelidakis G, Hosry J, Kyvernitakis A, Mahale P, Jiang Y, Miller E, Blechacz B, Naing A, Samaniego F, Kaseb A, Raad II, Granwehr BP. Sofosbuvir-Based Therapy in Hepatitis C Virus-Infected Cancer Patients: A Prospective Observational Study.Am J Gastroenterol. 2019;114:250-257. [PMID: 30410039 DOI: 10.1038/s41395-018-0383-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
35 Lopez Luis BA, Angulo-Medina L, Rodriguez-Diaz R, Soto-Ramírez LE. Baseline Hepatitis C Virus NS5A Resistance-Associated Polymorphisms in Patients With and Without Human Immunodeficiency Virus Coinfection in Mexico. Microb Drug Resist 2021. [PMID: 33794105 DOI: 10.1089/mdr.2020.0436] [Reference Citation Analysis]
36 Poudel KC, Poudel-Tandukar K. High prevalence and genotype distribution of hepatitis C virus in people living with HIV in Kathmandu, Nepal. Infect Dis (Lond) 2021;53:521-30. [PMID: 33729860 DOI: 10.1080/23744235.2021.1898046] [Reference Citation Analysis]